8.095USD+1.95%Mkt Cap: 811.80M USDP/E: —Last update: 2026-05-26
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap811.80M USD
Enterprise Value787.49M USD
Revenue (TTM)98.99M USD
Gross Profit63.85M USD
Net Income (TTM)-171.30M USD
Revenue/Share1.001 USD
Last Price8.095 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees154
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.64
PEG—
EV/EBITDA-3.92
EV/Revenue7.96
P/S8.26
P/B7.15
EPS (TTM)-2.00
EPS (Forward)-0.95
52W Range
6.66012% of range18.90
52W High18.90 USD
52W Low6.660 USD
Profitability
Gross Margin75.77%
Oper. Margin-265.18%
EBITDA Margin-202.99%
Profit Margin-203.25%
ROE-149.92%
ROA-52.28%
Growth
Revenue Growth184.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-170.87M USD
CapEx (TTM)339.00K USD
FCF Margin-99.28%
FCF Yield-12.11%
Net Debt-29.77M USD
Net Debt/EBITDA0.15
Balance Sheet
Debt/Equity0.84
Current Ratio4.94
Quick Ratio4.64
Book Value/Sh1.151 USD
Cash/Share2.024 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)25.20 USD
Target Range12.00 USD – 32.00 USD
# Analysts5
Ownership
Shares Out.99.30M
Float39.18M
Insiders16.29%
Institutions95.46%
Short Interest
Short Ratio17.2d
Short % Float38.06%
Short % Out.26.38%
Shares Short26.19M
Short (prev mo.)25.34M
Technical
SMA 508.201 (-1.3%)
SMA 2009.906 (-18.3%)
Beta0.80
S&P 52W Chg28.31%
Avg Vol (30d)1.81M
Avg Vol (10d)1.98M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—